GILD

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

KONDOR AI APP SURPASSES 20K DOWNLOADS, DOUBLING Q1 PROJECTIONS

Retrieved on: 
Wednesday, April 3, 2024
CBX, Software as a service, Shell, Entrepreneurship, Intelligence, Blockchain, London Stock Exchange, DIY, ARB, LLM, Collinge, Plant, App Store (iOS/iPadOS), Google Play, Red Bull, Artificial intelligence, Sony, Encounter, GILD, Hand, Medical device

LONDON, April 3, 2024 /PRNewswire/ -- Kondor (AQSE: KNDR), one of the first vision-based Artificial intelligence (AI) I assistants built for mobile devices announces that it has surpassed 20k downloads of its Kondor AI application.

Key Points: 
  • LONDON, April 3, 2024 /PRNewswire/ -- Kondor (AQSE: KNDR), one of the first vision-based Artificial intelligence (AI) I assistants built for mobile devices announces that it has surpassed 20k downloads of its Kondor AI application.
  • Kondor AI is available on the App Store, with a Google Play beta coming soon to North America.
  • With Kondor AI, users capture or upload photos, ask the AI image assistant a question and receive informative responses in an instant, all with a few simple taps.
  • For additional information on Kondor AI, please visit the official website and download Kondor AI today on the App Store .

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)

Retrieved on: 
Thursday, February 29, 2024
IGT, Gilead Sciences, Brodsky, Society, First, Sterling, GILD, Silver Strand (San Diego), Therapy, International Game Technology, Everi Holdings, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, CymBay will be acquired by Gilead Sciences, Inc. (Nasdaq - GILD).
  • Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
  • Under the terms of the agreement, Societal CDMO will be acquired by CoreRx, Inc. (“CoreRx”) for $1.10 per share in cash.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)

Retrieved on: 
Monday, February 12, 2024
Owens Corning, BMY, Gilead Sciences, ZeroFox, Brodsky, Bristol Myers Squibb, GILD, Therapy

BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • ZeroFox shareholders will receive $1.14 per share in an all-cash transaction with an enterprise value of approximately $350 million.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

AHF Slams Gilead Profiteering

Retrieved on: 
Tuesday, November 7, 2023
Infectious Diseases, Advocacy Group Opinion, Public Policy, Government, Healthcare Reform, Professional Services, Socially Responsible Investing, AIDS, Health, Other Policy Issues, San Francisco Chronicle, San Francisco Bay Area, Patent, HIV, AHF, Gilead Sciences, Q3, AIDS Healthcare Foundation, Assault, Safety, GILD, Patient, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) continued its assault on Gilead Sciences in its ongoing advocacy campaign against the Bay Area drugmaker over its incessant greed, patent manipulation, and obscene price hikes.

Key Points: 
  • AIDS Healthcare Foundation (AHF) continued its assault on Gilead Sciences in its ongoing advocacy campaign against the Bay Area drugmaker over its incessant greed, patent manipulation, and obscene price hikes.
  • Earnings advanced 20.5% and walloped GILD stock analysts’ expectations for $1.79.” While today’s earnings beat many analysts’ expectations, they also prompted new criticism from AHF over Gilead’s abhorrent drug pricing and policies.
  • Last month, AHF started running a weekly full-page, full-color newspaper ad in the San Francisco Chronicle and New Jersey’s Daily Record (Gilead’s new East Coast hometown newspaper).
  • AHF also sent letters to financial institutions that manage socially responsible investment funds urging them to divest their portfolios of Gilead stock holdings.

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

Retrieved on: 
Tuesday, September 5, 2023
Bispecific monoclonal antibody, Monoclonal antibody, Gilead Sciences, Therapy, CD3, Cancer, Macrogen, Research, Gilead, GILD, CD123, Pharmaceutical industry, MD

This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.

Key Points: 
  • This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.
  • Under the October 2022 agreement, MacroGenics will receive $15 million related to the nomination of a bispecific research program to be conducted by MacroGenics and funded by Gilead.
  • Pursuant to this agreement, which covers MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and up to two additional bispecific research programs, MacroGenics remains eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones.
  • MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.